Can AI-Driven Enzyme Design Enhance Neogen's (NEOG) Long-Term Food Safety Innovation Strategy?

• On August 11, 2025, Neogen Corporation announced it had entered into a collaboration with Biomatter to create new enzyme-based products using Biomatter's proprietary Intelligent Architecture platform, which combines artificial intelligence and physical modeling.
• This partnership merges Neogen’s analytical and technology capabilities with advanced AI-driven enzyme design, potentially broadening applications in food safety and enhancing future product innovation.
• We will explore how Neogen's move to use AI-powered enzyme design with Biomatter could influence its investment narrative moving forward.

The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's.

Neogen Investment Narrative Recap

For shareholders in Neogen, the core investment premise centers on recovery through food safety innovation, margin improvement, and more focused operations. The newest collaboration with Biomatter won't immediately address the core challenge: ongoing integration inefficiencies from the 3M Food Safety acquisition, which remain the biggest risk to near-term profit recovery. While leveraging AI for enzyme development could strengthen Neogen’s long-term growth story, its short-term catalyst is still operational stabilization and improved execution at its production facilities.

A recent announcement relevant to this theme is Neogen’s July launch of the Molecular Detection Assay – Listeria Right Now, offering rapid and user-friendly pathogen detection. This launch builds on Neogen's strengths in innovation, which could be enhanced by AI-driven enzyme design, but execution at scale and delivery on promised efficiency gains in the supply chain remain key.

In contrast, investors should also be aware of ongoing manual labor and excess costs from 3M Food Safety integration, as these...

Read the full narrative on Neogen (it's free!)

Neogen's outlook anticipates $859.1 million in revenue and $106.1 million in earnings by 2028. This scenario is based on a 1.3% annual revenue decline and an earnings increase of about $1.2 billion from current earnings of -$1.1 billion.

Uncover how Neogen's forecasts yield a $6.50 fair value, a 17% upside to its current price.

Exploring Other Perspectives

Simply Wall St Community members currently estimate Neogen’s fair value from US$6.50 to US$14.15, based on two individual analyses. In this context, persistent integration challenges and gradual margin recovery indicate why your views on profitability and innovation matter more than ever.

Explore 2 other fair value estimates on Neogen - why the stock might be worth over 2x more than the current price!

Build Your Own Neogen Narrative

Disagree with existing narratives? Create your own in under 3 minutes - extraordinary investment returns rarely come from following the herd.

• A great starting point for your Neogen research is our analysis highlighting 1 important warning sign that could impact your investment decision.
• Our free Neogen research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Neogen's overall financial health at a glance.

No Opportunity In Neogen?

Our daily scans reveal stocks with breakout potential. Don't miss this chance:

• Trump's oil boom is here - pipelines are primed to profit. Discover the 22 US stocks riding the wave.
• The latest GPUs need a type of rare earth metal called Dysprosium and there are only 27 companies in the world exploring or producing it. Find the list for free.
• We've found 19 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com